Platelet-rich therapies in the treatment of intravenous bisphosphonate-related osteonecrosis of the jaw: A report of 32 cases

Oral Oncology

Volumn 48, Issue 5, 2012, Pages 469-474

  Mozzati, Marco ^a   Gallesio, Giorgia ^a   Arata, Valentina ^a   Pol, Renato ^a   Scoletta, Matteo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Bisphosphonate; BRONJ; Complication; Oncology; PRGF; Tooth extraction

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; GROWTH FACTOR; PLASMA RICH IN GROWTH FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; JAW OSTEONECROSIS; MALE; ORAL SURGERY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; JAW; MALE; MIDDLE AGED; NEOPLASMS; PLATELET-RICH PLASMA; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84859937627     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2011.12.004     Document Type: Article

References (48)

1. Berenson JR. Treatment of hypercalcemia of malignancy with bisphosphonates. Semin Oncol 2002;29:12-8. (Pubitemid 36222938)
2. Coleman RE. Bisphosphonates: clinical experience. Oncologist 2004;9(4):14-27. (Pubitemid 39363165)
3. Mundy GR. Bisphosphonates and tumor burden. J Clin Oncol 2002;20:3191-2. (Pubitemid 34831513)
4. Ringe JD, Fardellone P, Kruse HP, Amling M, van der Geest SA, Moller G. Value of a new fixed-combination pack of bisphosphonate, calcium and vitamin D in the therapy of osteoporosis: results of two quantitative patient research studies. Drugs Aging 2009;26:241-53.
5. Conte P, Coleman R. Bisphosphonates in the treatment of skeletal metastases. Semin Oncol 2004;31:59-63. (Pubitemid 39370112)
6. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7. (Pubitemid 37064711)
7. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 2006;7:508-14. (Pubitemid 43779167)
8. Ruggiero S.L, Dodson T.B, Assael L.A, Landesberg R, Marx R.E, Mehrotra B. American association of oral and maxillofacial surgeons position paper on bisphosphonate related osteonecrosis of the jaw 2009 update. Aust Endod J 2009;35:119-130
9. Mignogna MD, Fedele S, Lo Russo L, Ciccarelli R, Lo Muzio L. Case 2 osteonecrosis of the jaws associated with bisphosphonate therapy. J Clin Oncol 2006;24:1475-7. (Pubitemid 46622016)
10. Ruggiero SL. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): initial discovery and subsequent development. J Oral Maxillofac Surg 2009;67:13-8.
11. Carlson ER, Basile JD. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009;67:85-95.
12. Pautke C, Bauer F, Tischer T, Kreutzer K, Weitz J, Kesting M, et al. Fluorescence-guided bone resection in bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg 2009;67:471-6.
13. Scoletta M, Arduino PG, Dalmasso P, Broccoletti R, Mozzati M. Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: a prospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;110:46-53.
14. Scoletta M, Arduino PG, Reggio L, Dalmasso P, Mozzati M. Effect of low-level laser irradiation on bisphosphonate-induced osteonecrosis of the jaws: preliminary results of a prospective study. Photomed Laser Surg 2010;28:179-84.
15. Stockmann P, Vairaktaris E, Wehrhan F, Seiss M, Schwarz S, Spriewald B, et al. Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up. Support Care Cancer 2010;18:449-60.
16. Anitua E. Plasma rich in growth factors: preliminary results of use in the preparation of future sites for implants. Int J Oral Maxillofac Implants 1999;14:529-35.
17. Anitua E, Sanchez M, Nurden AT, Nurden P, Orive G, Andia I. New insights into and novel applications for platelet-rich fibrin therapies. Trends Biotechnol 2006;24:227-34.
18. Anitua E, Sanchez M, Orive G, Andia I. The potential impact of the preparation rich in growth factors (PRGF) in different medical fields. Biomaterials 2007;28:4551-60. (Pubitemid 47271893)
19. Molina-Minano F, Lopez-Jornet P, Camacho-Alonso F, Vicente-Ortega V. Plasma rich in growth factors and bone formation: a radiological and histomorphometric study in New Zealand rabbits. Braz Oral Res 2009;23:275-80.
20. Anitua E, Orive G, Pla R, Roman P, Serrano V, Andia I. The effects of PRGF on bone regeneration and on titanium implant osseointegration in goats: a histologic and histomorphometric study. J Biomed Mater Res A. 2009;91:158-65.
21. Marx R. Oral and intravenous bisphosphonate-induced osteonecrosis of the jaws: history, etiology, prevention, and treatment. Hanover Park, I.L: Quintessence Publishing Co., Inc.; 2007.
22. Bianchi SD, Scoletta M, Cassione FB, Migliaretti G, Mozzati M. Computerized tomographic findings in bisphosphonate-associated osteonecrosis of the jaw in patients with cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;104:249-58.
23. Mozzati M, Martinasso G, Pol R, Polastri C, Cristiano A, Muzio G, et al. The impact of plasma rich in growth factors on clinical and biological factors involved in healing processes after third molar extraction. J Biomed Mater Res A 2010;95:741-6.
24. Wilde F, Heufelder M, Winter K, Hendricks J, Frerich B, Schramm A, et al. The role of surgical therapy in the management of intravenous bisphosphonates-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;100:100.
25. American Association of Oral Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369-76.
26. Graziani F, Cei S, La Ferla F, Cerri E, Itro A, Gabriele M. Association between osteonecrosis of the jaws and chronic high-dosage intravenous bisphosphonates therapy. J Craniofac Surg 2006;17:876-9. (Pubitemid 44470165)
27. Rayman S, Almas K, Dincer E. Bisphosphonate-related jaw necrosis: a team approach management and prevention. Int J Dent Hyg 2009;7:90-5.
28. Ficarra G, Beninati F, Rubino I, Vannucchi A, Longo G, Tonelli P, et al. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol 2005;32:1123-8. (Pubitemid 41499467)
29. Hewitt C, Farah CS. Bisphosphonate-related osteonecrosis of the jaws: a comprehensive review. J Oral Pathol Med 2007;36:319-28. (Pubitemid 46889876)
30. Gonzalez-Moles MA, Bagan-Sebastian JV. Alendronate-related oral mucosa ulcerations. J Oral Pathol Med 2000;29:514-8.
31. Kobayashi Y, Hiraga T, Ueda A, Wang L, Matsumoto-Nakano M, Hata K, et al. Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice. J Bone Miner Metab 2010;28:165-75.
32. Landesberg R, Cozin M, Cremers S, Woo V, Kousteni S, Sinha S, et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 2008;66:839-47. (Pubitemid 351522817)
33. Campisi G, Di Fede O, Musciotto A, Lo Casto A, Lo Muzio L, Fulfaro F, et al. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): run dental management designs and issues in diagnosis. Ann Oncol. 2007;18(6 vi):168-72.
34. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-91. (Pubitemid 351229318)
35. Magopoulos C, Karakinaris G, Telioudis Z, Vahtsevanos K, Dimitrakopoulos I, Antoniadis K, et al. Osteonecrosis of the jaws due to bisphosphonate use. a review of 60 cases and treatment proposals. Am J Otolaryngol 2007;28:158-63. (Pubitemid 46702356)
36. Montebugnoli L, Felicetti L, Gissi DB, Pizzigallo A, Pelliccioni GA, Marchetti C. BPs-associated osteonecrosis can be controlled by nonsurgical management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;104:473-7.
37. Wutzl A, Biedermann E, Wanschitz F, Seemann R, Klug C, Baumann A, et al. Treatment results of bisphosphonate-related osteonecrosis of the jaws. Head Neck 2008;30:1224-30.
38. Curi MM, Cossolin GS, Koga DH, Araujo SR, Feher O, dos Santos MO, et al. Treatment of avascular osteonecrosis of the mandible in cancer patients with a history of bisphosphonate therapy by combining bone resection and autologous platelet-rich plasma: report of 3 cases. J Oral Maxillofac Surg 2007;65:349-55. (Pubitemid 46131421)
39. Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR. Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;85:638-46. (Pubitemid 128641964)
40. Lee CY, David T, Nishime M. Use of platelet-rich plasma in the management of oral BPs-associated osteonecrosis of the jaw: a report of 2 cases. J Oral Implantol 2007;33:371-82.
41. Adornato MC, Morcos I, Rozanski J. The treatment of bisphosphonate- associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors. J Am Dent Assoc 2007;138:971-7.
42. Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2003;9:2893-7. (Pubitemid 36993246)
43. Del Fabbro M, Boggian C, Taschieri S. Immediate implant placement into fresh extraction sites with chronic periapical pathologic features combined with plasma rich in growth factors: preliminary results of single-cohort study. J Oral Maxillofac Surg 2009;67:2476-84.
44. Santini D, Vincenzi B, Avvisati G, Dicuonzo G, Battistoni F, Gavasci M, et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 2002;8:1080-4. (Pubitemid 34517643)
45. Marx RE. Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dent 2001;10:225-8.
46. Marx R, Garg A. Dental and craniofacial applications of platelet-rich plasma. Chicago: Quintessence Publishing; 2005.
47. Lopez-Jornet P, Camacho-Alonso F, Molina-Minano F, Vicente-Ortega V. Effects of plasma rich in growth factors on wound healing of the tongue Experimental study on rabbits. Med Oral Patol Oral Cir Bucal 2009;14:e425-8.
48. Sanchez M, Anitua E, Azofra J, Prado R, Muruzabal F, Andia I. Ligamentization of tendon grafts treated with an endogenous preparation rich in growth factors: gross morphology and histology. Arthroscopy 2010;26:470-80.